Home/Filings/4/0000950170-24-016428
4//SEC Filing

Fiedorek Fred T. 4

Accession 0000950170-24-016428

CIK 0001840574other

Filed

Feb 15, 7:00 PM ET

Accepted

Feb 16, 4:30 PM ET

Size

7.7 KB

Accession

0000950170-24-016428

Insider Transaction Report

Form 4
Period: 2024-02-14
Fiedorek Fred T.
Chief Medical Officer
Transactions
  • Award

    Restricted Stock Units

    2024-02-14+22,00022,000 total
    Common Stock (22,000 underlying)
  • Award

    Stock Option (right to buy)

    2024-02-14+90,00090,000 total
    Exercise: $12.75Exp: 2034-02-13Common Stock (90,000 underlying)
Footnotes (3)
  • [F1]The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028.
  • [F2]Each restricted stock unit represents a contingent right to receive one share of common stock.
  • [F3]On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028.

Documents

1 file

Issuer

Verve Therapeutics, Inc.

CIK 0001840574

Entity typeother

Related Parties

1
  • filerCIK 0001657185

Filing Metadata

Form type
4
Filed
Feb 15, 7:00 PM ET
Accepted
Feb 16, 4:30 PM ET
Size
7.7 KB